Abstract
Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharmacological effects of morning vs evening administration of empagliflozin (10 mg) in healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time.
Methods: An open label, sequential, two‐way crossover trial comprised of two periods with a washout period of 7 days. All participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet) in the evening, and after a seven-day washout period, the morning. Pharmacokinetics parameters (primary endpoints: t max (h), C max (ng/ml), AUC 0-t (ng.h/ml); secondary endpoints: AUC 0 to ∞(ng.h/ml)) were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE 0-24) was determined after method validation (glucose hexokinase method).
Results: T max increased by 35% in the evening phase compared to the morning phase, while C max decreased by -6.5% in the evening dose compared to the morning dose. Additionally, AUC 0 to ∞ increased in the evening phase by 8.25% compared to the morning phase. The mean cumulative amount of glucose excreted (UGE ( 0-24)) increased by 43% in the evening dose compared to the morning dose
Conclusion: Despite the difference in pharmacokinetics parameters between evening and morning doses, C max, AUC 0-t, AUC 0-∞, didn’t differ on the bioequivalence level. In addition, as UGE ( 0-24) didn’t statistically differ, thus, we can conclude that there is no statistical significance between the morning and evening doses.
Trial registration: Clinal Trials.gov, ID: NCT03895229 (registered on 29 th March 2019).
Keywords: Chronopharmacology, Empagliflozin 10 mg, Diabetes Mellitus, Bioequivalence, morning dose, evening dose, Pharmacokinetics, Pharmacodynamic, Circadian rhythm.
Introduction
Diabetes mellitus (DM) is one of the leading causes of death in the world. It has become one of the most critically medical and socially impacted diseases of the 21 st century. Moreover, it is considered an epidemic disease with very high proportion of cases discovered every year. According to the World Health Organization (WHO), the prevalence of DM worldwide almost doubled from 4.7% to 8.5% between 1980 and 2014, reaching approximately 422,000,000 of diabetic adults in 2014, particularly in low-and middle-income countries like Egypt 1. By 2040, around 642 million people will be diagnosed with DM 2, 3.
Chronopharmacology is the field of study concerned with the circadian rhythm of drugs regarding its pharmacokinetics/pharmacodynamics and pharmacological action; it also determines how the timing of the day may change the pharmacological action, pharmacokinetics and pharmacodynamics of the drug. Results of chronopharmacological studies are taken into practice under the umbrella of chronotherapy 4. In addition, chronopathology proposes that any disease, including DM, can happen as a result of disruption of biorhythms 5, 6.
The pathogenesis of DM involves different types of models, which explain various mechanisms of its pathogenetic development. For many years, the glucocentric approach has shaped the main theory of DM development. The new multigene concept shifted the theory of glucocentricity, and as a result, it added a new pathway for treating DM; many theories are presented which may open up our understanding on how circadian rhythm affects DM 5.
Circadian rhythm influences the kidney; the glomerular filtration rate (GFR) and renal plasma flow, together with tubular secretion and absorption, work promptly in the active phase and decrease activity in the inactive phase. These mechanisms are controlled by a circadian clock, which dominates multiple cellular functions, such as the transcription and translation of proteins, the addition of phosphorous or acetyl group, and even the ubiquitylation of protein (post transitional). Moreover, kidney functions (electrolyte excretion, urine volume and regulation of blood pressure) abide by circadian variation 7, 8.
These various circadian etiologies affecting the development of DM necessitate the study of how chronopharmacological studies on antihyperglycemic drugs can affect the outcome of the treatment. This is the aim of personalized medicine. However, there are only a few available chronopharmacological studies to date available for antihyperglycemic drugs 5.
In this study, we propose to investigate empagliflozin. Empagliflozin, which acts by inhibiting the sodium glucose co-transporter 2 (SGLT2) in the proximal tubules in the kidney, is indicated for two major isoforms (SGLT1 and SGLT2) in DM type 2, which are proposed for the sodium-glucose cotransporter (SGLT). SGLT2 is mainly expressed in the lumen of the small intestine and kidneys; SGLT2 takes part in the absorption/reabsorption of glucose induced by the sodium gradient across the cell membrane in the proximal tubules in the kidney 9. Empagliflozin shows high improvement in glucose metabolism and, hence, its homeostasis. When added to standard care, it demonstrates, along with its anti-glycemic effect, a decrease in the patients’ mortality rate attributed to the cardiovascular disease(s), hospitalization for heart failure, all-cause hospitalization, and all-cause mortality 10. As a result, in 2016, the FDA announced that empagliflozin is indicated for diabetic patients with heart failure 11. In addition, in 2021, a new drug application is being investigated for empagliflozin in reducing risk of mortality or hospitalization and preserve kidney function in diabetic and non-diabetic with heart failure 12, 13. Moreover, it has a positive impact on glycemic control and reductions in weight and normalization of circadian blood pressure rhythm (non-dipping) 9.
Empagliflozin (JARDIANCE ® 10 mg film coated tablet) is found in the market in two concentrations (10 or 25 mg), taken once daily with no rationale on the intake time between the morning versus the evening 10, 11.
Empagliflozin is swiftly absorbed after single escalating oral doses (0.5–800 mg) with a two phases decline. AUC 0-∞ and C max are directly proportional with increasing doses. Moreover, in a few studies administration of empagliflozin with food resulted in halting the absorption, and in addition, the total quantity of glucose excreted increased by increasing the doses; it inhibited 40% of reabsorbed glucose at the single daily doses 2.
The timing of drug intake can affect the circadian rhythm. For example, the blood pressure lowering drug Fimasartan shows pronounced blood pressure lowering (readjusting the dipping pattern) at night compared to morning dose. This is similar to our study drug, empagliflozin, which shows a provisional effect in restoring circadian blood pressure also at night in patients suffering from an imbalance in dipping blood pressure rhythm 14, 15.
In addition, since empagliflozin works on the kidneys’ proximal tubules, therefore, by examining the effect of inhibiting SGLT2 in the proximal tubules from a circadian rhythm point of view, it can add a new perspective in studying how the circadian rhythm can affect the timing of drug administration in the kidney.
The aim of this study is to examine the chronopharmacological characteristics of empagliflozin (10 mg film coated tablet) by comparing the antihyperglycemic effect (morning vs evening administration) on healthy adults, and to examine the influence of circadian rhythm on empagliflozin. Therefore, we examined for the first time the effect of the day and night dosing on the circadian rhythm for an antihyperglycemic drug, which may aid improving the proper use of this drug.
Methods
Study design
This open label, sequential trial consisted of two periods with a seven-day washout period and took place between 2 nd and 10 th October 2018. Participants were selected 21–27 days before the trial between the 3 rd of September to 26 th of September 2018. Figure 1 includes the trial study design.
Figure 1. Flow chart of the study design of the effect of morning vs evening administration of empagliflozin (Jardiance® 10mg film coated tablet; manufactured by Boehringer Ingelheim Pharma Gmbh & Co, Germany) on its pharmacokinetics and pharmacodynamics.
Ethical statement
The trial was conducted at the Drug Research Center, Cairo, Egypt in compliance with Good Clinical Practice and in accordance with the International Conference of Harmonization (ICH) guidance on general considerations for clinical trials and the Declaration of Helsinki. The trial was approved by the Ethics Committee (IRB) of the Faculty of Pharmacy of Ain Shams University (no.203) and the Drug Research Center. The trial was registered in ClinicalTrials.gov (ID: NCT03895229) on 2 nd April 2019. The trial was registered after the trial had been completed due to an administrative error. The authors confirm that all ongoing and related trials for this drug/intervention are registered.
Each participant provided written informed ethic to participate in the trial prior to enrolment.
Participants
Participants were selected 21–27 days before the trial and were recruited according to eligibility criteria from the drug research center volunteers’ database and volunteer referrals. In addition, dietary regimens (meals) were supplied in accordance with the FDA and Food and Nutrition Board, and all participants received the standard total caloric intake/day of fats (20–35%), carbohydrates (45–65 %) and protein (10–35%) 16.
Eligibility criteria
Eligible participants were non-smokers with good age-appropriate health conditions, as established by medical history, physical examination, and results of biochemistry, hematology and urine analysis testing four weeks prior to the study (see section Laboratory tests). Eligible participants required normal blood pressure and pulse rate according to reference normal ranges.
The sample excluded any participants who had been subjected to known enzyme-inducers/inhibitors within 30 days prior to the start of the study, and participants who took any medication less than two weeks prior to the trial starting date. Participants susceptible to allergic reactions to empagliflozin, or any other condition that might interfere with drug absorption, including prior surgery of the gastrointestinal tract, gastrointestinal diseases were excluded. Those with renal diseases, cardiovascular diseases, hepatic diseases, hematological disease or pulmonary disease, having dehydration, hypotension, urinary tract infections and cases of abnormal laboratory values were rejected. Finally, participants who had donated blood or who had been in multiple dosing study requiring a large volume of blood (more than 500 ml) to be drawn within six weeks preceding the start of the study were also excluded.
Laboratory tests
Screening assessments encompassed complete (past and present) medical history evaluation, physical examination and laboratory tests, namely: (1) biochemical tests of fasting blood sugar, serum urea, serum creatinine, serum glutamic-pyruvic transaminase, serum glutamic-oxaloacetic transaminase, cholesterol, triglycerides; high-density lipoprotein, low-density lipoprotein, hepatitis c virus antibody, human immunodeficiency virus, blood Group (A, B, AB, O) and RH-typing; (2) a complete blood count report; (3) a urine analysis report, which included physical examination, chemical examination and microscopical examination.
Intervention
The participants were allowed to eat a standard meal containing carbohydrates, protein and fats according to the allowed ratios of standard calories per day (2000 kcal/day).
The participants entered the Drug Research Center one day before the treatment began, in which they received their morning or evening treatment doses by a resident physician and a clinical pharmacist.
Each participant had to go to another room to receive the dose and then come back to the main room. Evening dose was given on the 2 nd of October and morning dose was on the 10 th of October 2018.
In order to increase patient compliance during the trial, incentives were offered, free meals (as above) and transportation after the end of the trial.
All participants received their evening does first, stayed for 24 hours to have their urine and blood tests; then came back 7 days later to receive their morning dose, and stayed for 24 hours for urine and bloods, then came back for a follow-up at 48 hours.
Eligible healthy participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet; manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG, Germany for Boehringer Ingelheim International GmbH, German) in the evening or morning 17.
In the evening phase, at around 7 pm, the participants were administered the evening oral dose followed by dinner. After the washout period (7 days), at around 9 am, the participants then received the morning oral dose followed by breakfast.
The trial medication was administered with a full glass of water. The participants were asked to fast for at least 12 hours before the dose of empagliflozin (JARDIANCE ® 10 mg) and the dose was administered under close supervision of a medical investigator.
Endpoints
Primary pharmacokinetic endpoint was to determine the effect of morning versus evening doses on pharmacokinetics parameters: T max (h), C max (ng/ml), AUC 0-t (ng.h/ml), while secondary pharmacokinetics parameter was AUC ( 0 to ∞) (ng.h/ml) 18.
Pharmacodynamic endpoint was to determine the cumulative UGE (cumulative amount of glucose excreted) over the 24 h in g/dl 18.
Pharmacodynamics evaluation
Urine samples were collected by urine collecting tube (1liter) for determination of UGE in g (urinary glucose excretion), which is the mean amount of glucose excreted in urine over the first 24 h after oral administration. Sampling intervals were 0 to 4, 4 to 8, 8 to 12 and 12 to 24 h after the administration of empagliflozin at the morning and evening doses.
Urine samples were stored at -80 °C before being sent to the clinical laboratory for analysis. Analysis was performed by the glucose hexokinase enzymatic method for determination of glucose concentration 19.
Cumulative UGE (mg) was calculated for each participant by multiplying the urine volume by the glucose concentration for each sampling interval in each period (morning or evening).
Pharmacokinetics evaluation and bioanalysis
Serial blood samples (0.5 ml) for determination of plasma empagliflozin concentrations were collected at 0 h pre-dose and then at 0.333, 0.667, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 h for period one (evening dose) and period two (morning dose). Bioanalytical method validation was done by the authors; blood samples treated with EDTA were centrifuged at 3500rpm for 5 minutes to get a plasma supernatant.
Plasma samples were analyzed by high performance liquid chromatography tandem mass spectrometry (HPLC- MS/MS) using an LC Agilent 1200 series and an Agilent 6410 Quadrupole mass spectrometer (Agilent Technologies, Inc., Santa Clara, CA) for determination of empagliflozin concentration in plasma. For preparation of plasma samples, 50ul of the internal standard dapagliflozin was added to an aliquot of 0.5ml plasma then vortex mixing was applied for 30 seconds. A liquid-liquid extraction by 2mls of diethyl ether-dichloromethane 60:40v/v was performed. After vortex mixing samples with the organic solvent for 2 minutes, samples were prone to phase separation at 3500rpm for 5 minutes in the centrifuge (Hermle Z 326K, Hermle Labortechnik GmbH, Wehingen, Germany). The clear supernatant was separated after centrifugation and evaporated under vacuum in the concentrator at 45 0C (Vacufuge® Plus, Eppendorf, Germany). Reconstitution of dry residue by the mobile phase (0.4% formic acid:Acetonitrile 17:83v/v) was performed prior to injection on LC/MS/MS. An aliquot of 5ul was injected on an isocratic system with a mobile phase composed of 0.4% formic acid: Acetonitrile 17:83% v/v and a C18 column as the stationary phase (Gemini C18 50 X 4.6mm, particle size 5um, Phenomenex Inc, Torrance, CA.) with a total run time of 3.1 minutes. Empagliflozin and dapagliflozin were determined by mass spectrometry in the multiple reaction monitoring mode (MRM). The mass to charge ratios (m/z) of precursor ions monitored for empagliflozin and dapagliflozin were 429.4 and 423.4 respectively with a common product ion m/z 207.1. The method of analysis showed a linear calibration range from 0.5 to 200 ng/ml with a correlation coefficient (r2=0.999) and average accuracy percent of 98.7%. Inter-day precision for quality control samples were below a percent relative standard deviation of 5.5% confirming a precision within the acceptable limits of validation.
Pharmacokinetics parameters of Empagliflozin were analyzed by Winnonlin™ software version 2.0 (Pharsight, California, Palo Alto, CA). C max, T max were calculated directly from the plasma concentration time curve (shown in Results section), while AUC 0-t and AUC 0 to ∞. were computed using the linear trapezoidal rule.
Safety and tolerability assessment
The subjects were followed up during and after one day of the study. Results obtained from the laboratory tests (biochemical, complete blood picture report, and urine analysis report) were done prior to the study with only participants with results within the normal range allowed to participate in the study. In addition, medical history and physical examination were done and evaluated by a physician in the research center prior to the start of the study. Adverse effects were recorded by participants during the two periods (night and day).
Statistical analysis
Based on a within subject variability of 18.7% for C max of empagliflozin 20, a calculated sample size of 16 subjects was sufficient to acquire a study power of 80% at a level of significance of 5% 21, 22.
All subjects were tested for the pharmacokinetics and pharmacodynamics endpoints; analysis of the study was intention to treat. Diurnal and nocturnal variability from morning and evening doses were assessed independently for all the pharmacokinetics and pharmacodynamics parameters.
Pharmacokinetics primary endpoints (C max, AUC 0-t) and secondary endpoint (AUC 0-∞) were tabulated; one-way analysis of variance (ANOVA) was used, the data was assessed as mean difference between the two phases. Results were shown as P-value, geometric mean with 90% CI (confidence interval). Pairs of logarithmic transformed data of the primary and the secondary of the endpoints were analyzed using SAS ® University edition statistics software (SAS ®, USA) to determine a statistical difference between the morning and evening phases. T max was analyzed by Pairwise comparisons using the Wilcoxon signed-rank test. Median and range for both morning and night data and difference in median and P value were reported.
Pharmacodynamics parameter (cumulative amount of glucose excreted) was shown as P-value, geometric mean with 90% CI. Assessment was done by comparing mean difference of cumulative amounts of urine excreted over the 24 h for each phase (morning or evening) by one-way analysis of variance (ANOVA) for determining a statistical difference between the morning and evening phases using SAS ® University edition statistics software. P-value of < 0.05 and 90% CI for a two-tailed test were used to assess the significant difference in the study hypothesis.
Results
Participant demographics
In total, 16 adult men participated in the study; median age was 26 years (range 18–55 years) with median body mass index of 24.285 kg/m 2 (range 20–30 kg/m 2). The baseline demographics of all study participants are shown in Table 1. All 16 participants completed the study (no drop out), and all results were included in the pharmacokinetics, pharmacodynamics.
Table 1. Baseline demographic and clinical characteristics of the 16 enrolled participants in the study.
| Variable, mean (SD) | Phase 1 (n=16) | Phase 2 (n=16) | |
|---|---|---|---|
| Age, years | 30.5 (12.4) | 30.5 (12.4) | |
| Weight, Kg | 74.5 (10.4) | 74.5 (10.4) | |
| BMI, Kg/m 2 | 24.9 (3.1) | 24.9 (3.1) | |
| Blood pressure, mmHg | Systole | 114.5 (5) | 111.5 (3.5) |
| Diastole | 74 (5) | 71.9 (4) | |
| Fasting blood sugar (mg/dl) | 84.4 (10.19) | 84.4 (10.19) | |
| Triglycerides (mg/dl) | 118.5 (33.25) | 118.5 (33.25) | |
| HDL (mg/dl) | 49.375 (9.07) | 49.375 (9.07) | |
| LDL (mg/dl) | 71.6125 (20.6) | 71.6125 (20.6) | |
Pharmacodynamics
Mean cumulative amount of glucose excreted from a single dose of empagliflozin (10 mg) over the 24 hours in the evening (Phase 1) and morning (Phase 2) doses are shown in Table 2 ( Figure 2 and Figure 3). Mean UGE (0–24) for the evening dose (phase 2) was 69 (CV%=43.4), which was higher compared to the morning (phase 1), at 39 (CV%=41). Geometric mean results comparing the evening and morning doses for the log transformed UGE values was 116.7 (90% Cl 79.8-170.8; P=0.7317).
Figure 2. Cumulative amount of glucose excreted for the evening (phase 1) and morning (phase 2) after administration of empagliflozin 10 mg.
Figure 3. Cumulative amount of glucose excreted over the 24 h for phase 1 and phase 2 after administration of single oral dose of empagliflozin 10 mg.
Table 2. Cumulative amount of glucose excreted after single dose administration of empagliflozin 10 mg.
| Parameter, mean±SD | Time
intervals |
Phase 1
(n=16) |
Phase 2
(n=16) |
|---|---|---|---|
| Cumulative amount of
glucose excreted (UGE) (g/dl) |
(0-4) h | 23.5±10 | 19±22 |
| (4-8) h | 13±7 | 14±10 | |
| (8-12) h | 21±16 | 9±6 | |
| (12-24) h | 69±30 | 39±16 |
Pharmacokinetics
Evening and morning doses of empagliflozin once daily were rapidly absorbed (in favor the morning dose) with peak median T max ranged between 2.5 (interquartile range (IQR) 1.25) to 1.625 (IQR 1.3) h post dose (P=0.063), reaching the maximum concentration between 125.60±30.7 (24.4%) to 117.9±32 (27.16%) g (P=0.324). The latter was followed by the slow elimination phase with elimination half-lives in the evening and morning doses of 7.2 (IQR 1.6) to 7 (IQR1.4) h, respectively ( Table 3, Figure 4).
Figure 4. Linear (left panel) and semi-logarithmic plot (right panel) for average empagliflozin 10 mg plasma concentration (ng/ml) after evening (phase 1) and morning (phase 2) doses.
Table 3. Pharmacokinetics findings of empagliflozin 10 mg.
| Parameter | Phase 1
(n=16) |
Phase 2
(n=16) |
P-value |
|---|---|---|---|
| T
max, h, median
(interquartile range) |
2.5 (1.25) | 1.625 (1.3) | 0.063 |
| C max, ng/ml, mean (SD) | 118 (32) | 125.6 (30.7) | 0.324 |
| AUC
0-t, ng.h/ml, mean
(SD) |
960 (157) | 888 (187) | 0.057 |
| AUC
0-∞, ng.h/ml, mean
(SD) |
980 (161.6) | 899 (189) | 0.036 |
In addition, the total exposure of the drug in a form of the area under the curve (AUC 0-t) between the morning and evening doses ranged from 888 (21.05%) to 960 (16.35%) (P=0.057). AUC 0-∞ ranged between 899 (21.02%) to 980 (16.4%) (P=0.036) ( Table 3, Figure 4). All the findings above suggests a linear pharmacokinetics relationship with time.
In addition, the geometric mean results of comparing log transformed C max, AUC 0-T and AUC 0-∞ for the evening and morning doses were 93.6 (90% Cl 83.707-104.82), 108.9 (90% Cl 101.274-117.297) and 109.823, (90% Cl 102.243-117.964), respectively.
The total exposure of the drug measured by AUC 0-t relative to the extrapolated total AUC 0-∞ of empagliflozin was slightly higher for evening than morning doses (98.776±0.541 vs 98.030±0.794).
Safety analysis
No adverse events were detected from empagliflozin 10 mg in this study. The drug was well tolerated for all participants. Vital signs before, during and after the end of the study (blood pressure, pulse) were within normal ranges. Clinical and lab values were all evaluated to be within normal values.
Discussion
Chronopathology proposes that any disease, including DM, may occur as a result of disruption of biorhythms 23. The effect of circadian clock on the kidney may affect the pharmacokinetics and/or pharmacodynamics of many drugs, especially those that exert their mechanism of action in the kidney 7. Moreover, circadian clock proteins control most hormones, enzymes, and transport mechanisms related to glucose metabolism 24. The following examples show different techniques on how circadian rhythm influence the kidney’s action: it has been described that renal function cycles over the 24 h and follows rhythmicity in its action, of note, GFR is influenced by many factors such as; systemic blood pressure, renal blood flow, afferent and efferent arteriolar resistance regulation, sympathetic system and hormones as renin and vasopressin 25.
Factors affecting GFR also affect other mechanisms within the kidney. Stimulation of the sympathetic nervous system influences renin secretion and renal sodium reabsorption (which can affect the action of our study drug) 25. Previous studies showed that SGLT2 expression in the proximal tubules is increased in DMT2, which may suggest that further studies to be done on the expression of SGLT1 and SGLT2 at the proximal tubules in the kidney (in which empagliflozin inhibit) are required 14.
Our study examined the effect of the SGLT2i with empagliflozin, taking into account that the transport of solutes in and out of the kidney are controlled by the circadian clock. It has been shown that NH3 and SGLT1 are controlled by circadian oscillations proteins (Per 1 and BMA1), affecting the mRNA transcription 26.
Other studies determined the mechanism and the level of involvement of the circadian clock genes and circadian rhythms in the proximal tubule cellular Na+/H+ ex- changer 3 (NH3) transporter. In addition to other mutations in circadian clock proteins, rhythmic oscillations involved in NH3 activity are directly related to positive daily variations in sodium and water transport of the proximal cells 27. NH3 expression is activated in the dark cycle and increases during a food intake 26, 28.
As sodium-hydrogen exchanger is affected by the circadian clock and, due to the link between empagliflozin (SGLT2i) and sodium-hydrogen exchanger, contributes to preventing heart failure. We recommend performing further studies on the effect of circadian rhythm on the action of SGLT2 inhibitors in specific and antihyperglycemic agents in general 29.
Circadian clock genes appear to be involved in every biological process in the human body. Currently, there is a lack of studies examining and determining the effect of chronopharmcology on antihyperglycemic drugs and drugs that exert their activity on the kidney. We recommend more chronopharmacological studies for antihyperglycemic drugs, either working on insulin secretion level or, as per our study, or drugs, which exert their mechanism of action on the kidney 5, 24.
A few recent studies have started to address the relationship between chronopharmacology and antihyperglycemic drugs. One recent study examined the effect of administrating dapagliflozin on high-fat diet-induced obesity in mice; the results of the study were promising and suggest that dapagliflozin follows chronopharmacology as plasma glucose, insulin levels and adipose adipokines decreased in the light phase 30.
Empagliflozin (JARDIANCE®) is available in two doses: 10 and 25 mg 31. We examined the 10 mg dose. Empagliflozin can be taken once daily (without rationale on its timing) as oral bioavailability of empagliflozin is high (higher t ½) 2. In the current study, empagliflozin 10 mg once daily in the morning or evening was rapidly absorbed, reaching the peak t max (C max) range between 2.5 and 1.625 h post dose, which similar to other previous studies on diabetic patients and healthy volunteers (1.5 to 2.1 h) 2, 32, 33. Absorption followed by the slow elimination phase with approximately the same elimination half-life in the evening and morning doses (7.278–7.327 h), which appeared shorter compared to previous studies that reached up to 13 h 2, 18.
The results of the current study showed that the total exposure of the drug measured by AUC 0-t relative to the extrapolated total AUC 0-∞ of empagliflozin was slightly higher for evening than morning doses (98.776±0.541, 98.030±0.794). On the other hand, UGE (0–24) for the evening dose was 69 g, compared to the morning phase, which was quite low at 39 g. Comparing these results to previous studies examining once daily dose of empagliflozin 10 mg, UGE 0–24 was 47.9 in healthy Caucasian and 50.6 g in healthy Japanese populations, respectively 21, 34. Moreover, in diabetic patients it ranged between 46.3 and 89.8 for the single dose to all doses of empagliflozin 2.
In studies done on diabetic patients, UGE 0–24 for the single dose of 10 mg ranged between 74.9 g and 77.9 g 32, 33. In this study, although the UGE 0–24 for the evening dose was higher, it didn’t reach a statistically significant level 35.
Moreover, the study on healthy Japanese participants showed that as the exposure increased (C max and AUC 0-∞), the UGE increased, which might correlate with our study findings (higher AUC 0-∞, UGE 0–24) favoring the night dose, except that C max didn’t differ between morning and evening doses 21.
The reason behind the higher UGE (0–24) for the evening dose may be attributed to the short duration of the study or may result from the effect of food since the dinner meal is always higher in calories, compared to the morning meal. However, previous studies that examined the role of food on empagliflozin (50 mg) showed that UGE 0–24 didn’t differ significantly between the fasted and fed state, with 71.7 g (13.6) and 75.9 g (17.9) mean (SD) respectively in healthy volunteers 34. Moreover, another study, done on the 25 mg dose, showed a non-significant effect with food administration (geometric mean 84.04, 90% CI 80.86-87.34) for the AUC 0-∞. 36. As a result, due to the limited studies on the effect of food on the morning and evening doses from the pharmacokinetics and pharmacodynamics perspective, further studies may be required.
Due to the above-mentioned functions of empagliflozin, we studied the effect of circadian rhythm and its time of administration regarding its pharmacokinetics and pharmacodynamics parameters, as we aim to achieve the best use of the drug, towards implementing personalized medicine.
This study was a pilot, done on healthy participants to limit confounders (other drugs or commodities) that can affect the study aim. Other studies performed on DM patients (their characteristics and physiological effects) are recommended to further explain if circadian rhythm can affect the pharmacokinetics and pharmacodynamics of the drug and thus efficacy of antihyperglycemic drugs. In addition, more studies can be performed addressing the role of pharmacogenetics changes and chronopharmacology.
Conclusion
Although there was a difference in the overall exposure of the empagliflozin in the morning vs evening doses (P value was significant for AUC 0-t and AUC 0-∞), they all were within the bioequivalence range. The difference in the other empagliflozin pharmacokinetic parameters between the evening and morning doses were non-significant. In addition, (UGE 0–24) was higher for the evening dose, but it didn’t reach a significant level. Taken together, the findings of the current study provide the first evidence that there is non-significant difference in the pharmacokinetics and pharmacodynamics effects between evening and morning dosing of empagliflozin 10 mf film-coated tablets.
Data availability
Underlying data
Dryad: Demographic data, https://doi.org/10.5061/dryad.gqnk98smc 37.
This project contains the following underlying data:
Data file 1: (Demographic data of the participant at before the start of the Evening dose)
Data file 2: (Demographic data of the participant at before the start of the Morning dose)
Dryad: Pharmacodynamics parameters, https://doi.org/10.5061/dryad.k0p2ngf7b 38.
This project contains the following underlying data:
Data file 1 (Cumulative amount of glucose excreted over the 24 hours at the Morning dose)
Data file 2 (Cumulative amount of glucose excreted over the 24 hours at the Evening dose)
Data file 3 (Pharmacodynamics evaluation Urinary glucose secretion)
Data file 4 (Pharmacodynamics parameters of Morning and Evening doses of Empagliflozin)
Dryad: Pharmacokinetics parameters, https://doi.org/10.5061/dryad.brv15dv8j 39.
This project contains the following underlying data:
Data file 1 (Plasma concentration(s) levels of the 16 participants at the Evening dose)
Data file 2 (Plasma concentration(s) levels of the 16 participants at the Morning dose)
Data file 3 (Pharmacokinetics parameters of the 16 participants at the Evening dose)
Data file 4 (Pharmacokinetics parameters of the 16 participants at the Morning dose)
Data file 5 (AUC0-t and AUC0-inf of the 16 participants for both evening and morning doses).
Extended data
Dryad: Bioanalytical method validation, https://doi.org/10.5061/dryad.brv15dv8j 39.
Dryad: Protocol, case report(s), ethics approvals, inclusion and exclusion criteria, https://doi.org/10.5061/dryad.7h44j0zt1 40.
This project contains the following underlying data:
Data file 1: (The trial protocol)
Data file 2: (Empty form of case report) this file is not at https://doi.org/10.5061/dryad.7h44j0zt1
Data file 4: (Inclusion and Exclusion criteria for the enrollment of the participants in the trial)
Data file 5: (Ethics committee approval(s) of AinShms University)
Reporting guidelines
Dryad: TREND checklist for ‘The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover non-randomised trial’, https://doi.org/10.5061/dryad.gqnk98smc 37.
Data is licensed under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication license.
Acknowledgements
I thank Yulia Kovalenko, Misr International University for her assistance in revising the manuscript.
Funding Statement
The author(s) declared that no grants were involved in supporting this work.
[version 1; peer review: 2 approved
References
- 1. Javeed N, Matveyenko AV: Circadian Etiology of Type 2 Diabetes Mellitus. Physiology (Bethesda). 2018;33(2):138–50. 10.1152/physiol.00003.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Scheen AJ: Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Clin Pharmacokinet. 2014;53(3):213–25. 10.1007/s40262-013-0126-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Bonora E, DeFronzo RA: Diabetes Complications, Comorbidities and Related Disorders.2018;451–471. 10.1007/978-3-030-36694-0 [DOI] [Google Scholar]
- 4. De Lavallaz L, Musso CG: Chronobiology in nephrology: the influence of circadian rhythms on renal handling of drugs and renal disease treatment. Int Urol Nephrol. 2018;50(12):2221–8. 10.1007/s11255-018-2001-z [DOI] [PubMed] [Google Scholar]
- 5. Bunyatyan ND, Bukhtiyarova IP, Drogovoz SM, et al. : Influence of Human Biorhythms on the Blood Glucose Level and the Efficacy of Hypoglycemic Drugs (Review). Pharm Chem J. 2017;51(5):399–401. 10.1007/s11094-017-1621-4 [DOI] [Google Scholar]
- 6. Raj GM, Raveendran R: Introduction to Basics of Pharmacology and Toxicology.Introduction to Basics of Pharmacology and Toxicology.2019;1. 10.1007/978-981-32-9779-1 [DOI] [Google Scholar]
- 7. Firsov D, Bonny O: Circadian rhythms and the kidney. Nat Rev Nephrol. 2018;14(10):626–35. 10.1038/s41581-018-0048-9 [DOI] [PubMed] [Google Scholar]
- 8. Olaoye OA, Masten SH, Mohandas R, et al. : Circadian Clock Genes in Diabetic Kidney Disease (DKD). Curr Diab Rep. 2019;19(7):42. 10.1007/s11892-019-1156-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Fioretto P, Zambon A, Rossato M, et al. : SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016;39 Suppl 2:S165–71. 10.2337/dcS15-3006 [DOI] [PubMed] [Google Scholar]
- 10. Wanner C, Lachin JM, Inzucchi SE, et al. : Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–29. 10.1161/CIRCULATIONAHA.117.028268 [DOI] [PubMed] [Google Scholar]
- 11. FDA: JARDIANCE (empagliflozin) Prescribing Information.2016;1–34. Reference Source [Google Scholar]
- 12. Empagliflozin in Heart Failure. N Engl J Med. 2021;384(4):384–8. 10.1056/NEJMc2033669 [DOI] [PubMed] [Google Scholar]
- 13. Shaw ML: Jardiance 1 Step Closer to FDA Approval for Use in Heart Failure. Am J Manag Care. 2021. Reference Source [Google Scholar]
- 14. Takeshige Y, Fujisawa Y, Rahman A, et al. : A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res. 2016;39(6):415–22. 10.1038/hr.2016.2 [DOI] [PubMed] [Google Scholar]
- 15. Chung WB, Ihm S, Jang S, et al. : Effect of high dose fimasartan on changes of daytime and nighttime blood pressure compared to high dose valsartan. J Hypertens. 2018;36(p e149):2018. 10.1097/01.hjh.0000539396.89580.03 [DOI] [Google Scholar]
- 16. Institute of Medicine, Food and Nutrition Board, Panel on Macronutrients: et al. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.2005. 10.17226/10490 [DOI] [PubMed] [Google Scholar]
- 17. Ndefo UA, Anidiobi NO, Basheer E, et al. : Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. P T. 2015;40(6):364–8. [PMC free article] [PubMed] [Google Scholar]
- 18. Macha S, Brand T, Meinicke T, et al. : Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Clin Ther. 2015;37(8):1789–96. 10.1016/j.clinthera.2015.06.003 [DOI] [PubMed] [Google Scholar]
- 19. Galant AL, Kaufman RC, Wilson JD: Glucose: Detection and Analysis. Food Chem. 2015;188:149–60. 10.1016/j.foodchem.2015.04.071 [DOI] [PubMed] [Google Scholar]
- 20. Therapeutic Goods Administration (TGA) commonwealth of Australia, Australian Public Assessment Report (AUSPAR) Rekovelle: Extract from the Clinical Evaluation Report for empagliflozin.2016; [cited 2020 Mar 25]. Reference Source [Google Scholar]
- 21. Sarashina A, Koiwai K, Seman LJ, et al. : Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213–9. 10.2133/dmpk.dmpk-12-rg-082 [DOI] [PubMed] [Google Scholar]
- 22. Brand T, Macha S, Mattheus M, et al. : Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29(10):889–99. 10.1007/s12325-012-0055-3 [DOI] [PubMed] [Google Scholar]
- 23. Jough SS, Singh SP, Singh Y, et al. : Chronopharmacology: Recent Advancements in the Treatment of Diabetes Mellitus through Chronotherapy. Int J Pharm Pharm Sci. 2017;9(2):87–99. Reference Source [Google Scholar]
- 24. Jakubowicz D, Wainstein J, Landau Z, et al. : Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017;40(11):1573–9. 10.2337/dc16-2753 [DOI] [PubMed] [Google Scholar]
- 25. Wuerzner G, Firsov D, Bonny O: Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrol Dial Transplant. 2014;29(8):1475–80. 10.1093/ndt/gft525 [DOI] [PubMed] [Google Scholar]
- 26. Solocinski K, Richards J, All S, et al. : Transcriptional regulation of NHE3 and SGLT1 by the circadian clock protein per1 in proximal tubule cells. Am J Physiol Renal Physiol. 2015;309(11):F933–42. 10.1152/ajprenal.00197.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Wei N, Gumz ML, Layton AT: Predicted effect of circadian clock modulation of NHE3 of a proximal tubule cell on sodium transport. Am J Physiol Renal Physiol. 2018;315(3):F665–76. 10.1152/ajprenal.00008.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Johnston JG, Pollock DM: Circadian regulation of renal function. Free Radic Biol Med. 2018;119:93–107. 10.1016/j.freeradbiomed.2018.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Packer M, Anker SD, Butler J, et al. : Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiol. 2017;2(9):1025–9. 10.1001/jamacardio.2017.2275 [DOI] [PubMed] [Google Scholar]
- 30. Yoshioka H, Ohishi R, Hirose Y, et al. : Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice. Obes Res Clin Pract. 2019;13(5):505–10. 10.1016/j.orcp.2019.08.001 [DOI] [PubMed] [Google Scholar]
- 31. Jardiance.Diabetes.co.uk.2019. Reference Source [Google Scholar]
- 32. Heise T, Seewaldt-Becker E, Macha S, et al. : Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–621. 10.1111/dom.12073 [DOI] [PubMed] [Google Scholar]
- 33. Heise T, Seman L, Macha S, et al. : Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331–45. 10.1007/s13300-013-0030-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Seman L, Macha S, Nehmiz G, et al. : Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(2):152–61. 10.1002/cpdd.16 [DOI] [PubMed] [Google Scholar]
- 35. Laffel LMB, Tamborlane WV, Yver A, et al. : Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabet Med. 2018;35(8):1096–104. 10.1111/dme.13629 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Macha S, Jungnik A, Hohl K, et al. : Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(11):873–9. 10.5414/cp201948 [DOI] [PubMed] [Google Scholar]
- 37. ElDash R: Demographic data. Dryad. 2021. 10.5061/dryad.gqnk98smc [DOI] [Google Scholar]
- 38. ElDash R: Pharmacodynamics parameters. Dryad.Dataset,2021. 10.5061/dryad.k0p2ngf7b [DOI] [Google Scholar]
- 39. ElDash R: Pharmacokinetics parameters. Dryad. 2021. 10.5061/dryad.brv15dv8j [DOI] [Google Scholar]
- 40. ElDash R: Protocol, case report(s), informed consent, inclusion and exclusion criteria. Dryad. 2021. 10.5061/dryad.7h44j0zt1 [DOI] [Google Scholar]